Heart attack

April 27, 2019

Erythropoietin/Haematopoietin-derived peptide protects against cardiomyopathy: Intracardiac/Epicardial injection of Cyclin helix B peptide (CHBP) protects against Cardiomyopathy: Cyclin helix B peptide (CHBP) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy, via upregulation of its target gene, 27/April/2019, 10.45 pm

Introduction: What they say A recent study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart […]
April 26, 2019

Embryo-derived peptide protects against cardiomyopathy: Intracardiac/Epicardial injection of Synthetic PreImplantation factor (sPIF) protects against Cardiomyopathy: Synthetic PreImplantation factor (sPIF) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy, via upregulation of its target gene, 26/April/2019, 11.10 pm

Introduction: What they say A recent study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart […]
April 25, 2019

Nucleostemin-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Nucleostemin, a nucleolus protein known to play a role in cell cycle progression, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 25/April/2019, 6.54 am

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was […]
April 24, 2019

Canagliflozin-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Canagliflozin (Brand name: Invokana, Sulisent, Prominad), a Sodium-glucose co-transporter 2 inhibitor used to treat TIIDM, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 24/April/2019, 7.37 am

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was […]